Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Eva-Maria Demmerath"'
Autor:
Christian Molnar, Sheila Bohler, Jovana Rajak, Julia Miriam Weiss, Irene Gonzalez-Mendez, Geoffroy Andrieux, Eva-Maria Demmerath, Madeleine Wahl, Lena Wendeburg, Gudrun Göhring, Brigitte Strahm, Doris Steinemann, Martina Rudelius, Melanie Börries, Leticia Quintanilla-Martinez, Charlotte M. Niemeyer, Verena Labi, Miriam Erlacher
Publikováno v:
EJC Paediatric Oncology, Vol 2, Iss , Pp 100069- (2023)
Externí odkaz:
https://doaj.org/article/eb53d0919a71441d88fd83a5986a697d
Autor:
Sheila Bohler, Sehar Afreen, Juncal Fernandez-Orth, Eva-Maria Demmerath, Christian Molnar, Ying Wu, Julia Miriam Weiss, Venugopal Rao Mittapalli, Lukas Konstantinidis, Hagen Schmal, Mirjam Kunze, Miriam Erlacher
Publikováno v:
Haematologica, Vol 106, Iss 12 (2020)
BH3-mimetics inhibiting anti-apoptotic BCL-2 proteins represent a novel and promising class of antitumor drugs. While the BCL-2 inhibitor venetoclax is already approved by the Food and Drug Administration, BCL-XL and MCL-1 inhibitors are currently in
Externí odkaz:
https://doaj.org/article/56e18fa348d74b2baa4702881af13610
Publikováno v:
Haematologica, Vol 104, Iss 4 (2019)
Myelosuppression is a major and frequently dose-limiting side effect of anticancer therapy and is responsible for most treatment-related morbidity and mortality. In addition, repeated cycles of DNA damage and cell death of hematopoietic stem and prog
Externí odkaz:
https://doaj.org/article/582410c2d04f4dd1bf96d25b800f8522
Autor:
Thomas Lehrnbecher, Ulrich Sack, Carsten Speckmann, Andreas H Groll, Andreas Boldt, Benjamin Siebald, Simone Hettmer, Eva-Maria Demmerath, Judith Reemtsma, Barbara Schenk, Sandra Ciesek, Jan-Henning Klusmann, Christian Jassoy, Sebastian Hoehl
Publikováno v:
Clinical Infectious Diseases. 76:e510-e513
Our study in 21 pediatric cancer patients demonstrates that 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccine (BioNTech/Pfizer) elicited both humoral and cellular immunity in most patients during chemothera
Autor:
Thomas, Lehrnbecher, Ulrich, Sack, Carsten, Speckmann, Andreas H, Groll, Andreas, Boldt, Benjamin, Siebald, Simone, Hettmer, Eva Maria, Demmerath, Barbara, Schenk, Sandra, Ciesek, Jan Henning, Klusmann, Christian, Jassoy, Sebastian, Hoehl
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
Our study in 21 pediatric cancer patients demonstrates that three doses of SARS-CoV-2 mRNA vaccine (BioNTech/Pfizer) elicited both humoral and cellular immunity in most patients during chemotherapy. Immunity was stronger in children with solid tumors
Autor:
Eva-Maria Demmerath, Christian Molnar, Venugopal Rao Mittapalli, Sheila Bohler, Miriam Erlacher, Lukas Konstantinidis, Ying Wu, Hagen Schmal, Mirjam Kunze, Juncal Fernandez-Orth, Sehar Afreen, Julia Miriam Weiss
Publikováno v:
Haematologica
BH3-mimetics inhibiting anti-apoptotic BCL-2 proteins represent a novel and promising class of antitumor drugs. While the BCL-2 inhibitor venetoclax is already approved by the Food and Drug Administration, BCL-XL and MCL-1 inhibitors are currently in
Publikováno v:
Haematologica
Myelosuppression is a major and frequently dose-limiting side effect of anticancer therapy and is responsible for most treatment-related morbidity and mortality. In addition, repeated cycles of DNA damage and cell death of hematopoietic stem and prog
Autor:
Alexandra Müller, Sehar Afreen, Julia Miriam Weiss, Eva-Maria Demmerath, Kristina Schachtrup, Jonas S. Jutzi, Sheila Bohler, Mirjam Kunze, Miriam Erlacher
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 11, Iss 1, Pp 1-15 (2020)
Cell Death and Disease, Vol 11, Iss 1, Pp 1-15 (2020)
The anti-apoptotic BCL-2 proteins (BCL-2, BCL-XL, MCL-1, A1, BCL-W) counteract apoptotic signals emerging during development and under stress conditions, and are thus essential for the survival of every cell. While the “BCL-2 addiction” of differ